To manage poorly controlled hypertension in patients already taking a calcium channel blocker, the recommended next step is to add an ACE inhibitor, an angiotensin receptor blocker (ARB), or a thiazide-like diuretic. In this particular case, since the patient is black, an ARB is the preferred choice. Beta-blockers like metoprolol are not commonly used for hypertension management. Increasing the dose of amlodipine may lead to more side effects, so it is generally better to add multiple drugs at lower doses instead of increasing the dose of one drug to its maximum.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

In this clinical scenario, the patient presents with well-defined patchy hair loss on the scalp, which is characteristic of alopecia areata. This autoimmune condition can lead to significant psychological distress, making effective management crucial. The most appropriate management strategy involves the use of topical corticosteroids, which are anti-inflammatory agents that can help reduce the immune response in the affected areas, promoting hair regrowth.

Additionally, referring the patient to a dermatologist is advisable for further evaluation and potential advanced treatment options, especially if the condition is extensive or does not respond to initial therapy. Other options presented are less suitable for this case. For instance, topical 5-fluorouracil (5-FU) is primarily used for actinic keratosis and superficial basal cell carcinoma, not for alopecia areata. An autoimmune screen may be considered in certain cases, but it is not routinely necessary for alopecia areata unless there are other clinical indications. Topical ketoconazole is an antifungal treatment and is not indicated for alopecia areata.

Key Takeaways: – Alopecia areata is an autoimmune condition that can cause significant emotional distress. – Topical corticosteroids are effective in managing localized alopecia areata. – Referral to a dermatologist is important for comprehensive care and management options. – Other treatments like 5-FU and ketoconazole are not appropriate for this condition.

Understanding Neuropathic Pain and its Management

Neuropathic pain is a type of pain that occurs due to damage or disruption of the nervous system. It is a complex condition that is often difficult to treat and does not respond well to standard painkillers. Examples of neuropathic pain include diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and prolapsed intervertebral disc.

To manage neuropathic pain, the National Institute for Health and Care Excellence (NICE) updated their guidance in 2013. The first-line treatment options include amitriptyline, duloxetine, gabapentin, or pregabalin. If the first-line drug treatment does not work, patients may try one of the other three drugs. Unlike standard painkillers, drugs for neuropathic pain are typically used as monotherapy, meaning that if they do not work, patients should switch to a different drug rather than adding another one.

Tramadol may be used as rescue therapy for exacerbations of neuropathic pain, while topical capsaicin may be used for localized neuropathic pain, such as post-herpetic neuralgia. Pain management clinics may also be useful for patients with resistant problems. However, it is important to note that for some specific conditions, such as trigeminal neuralgia, the guidance may vary, and carbamazepine may be used as a first-line treatment. Overall, understanding neuropathic pain and its management is crucial for improving the quality of life for patients suffering from this condition.

To convert from oral to subcutaneous morphine, divide the oral dose by two. In this case, the recommended subcutaneous morphine dose is 5mg four times daily, which is equivalent to 10mg of oral morphine four times daily. As the patient’s pain is currently well controlled, there is no need to adjust the analgesia dose.

Palliative care prescribing for pain is guided by NICE and SIGN guidelines. NICE recommends starting treatment with regular oral modified-release or immediate-release morphine, with immediate-release morphine for breakthrough pain. Laxatives should be prescribed for all patients initiating strong opioids, and antiemetics should be offered if nausea persists. Drowsiness is usually transient, but if it persists, the dose should be adjusted. SIGN advises that the breakthrough dose of morphine is one-sixth the daily dose, and all patients receiving opioids should be prescribed a laxative. Opioids should be used with caution in patients with chronic kidney disease, and oxycodone is preferred to morphine in patients with mild-moderate renal impairment. Metastatic bone pain may respond to strong opioids, bisphosphonates, or radiotherapy, and all patients should be considered for referral to a clinical oncologist for further treatment. When increasing the dose of opioids, the next dose should be increased by 30-50%. Conversion factors between opioids are also provided. Opioid side-effects are usually transient, such as nausea and drowsiness, but constipation can persist. In addition to strong opioids, bisphosphonates, and radiotherapy, denosumab may be used to treat metastatic bone pain.

Overall, the guidelines recommend starting with regular oral morphine and adjusting the dose as needed. Laxatives should be prescribed to prevent constipation, and antiemetics may be needed for nausea. Opioids should be used with caution in patients with chronic kidney disease, and oxycodone is preferred in patients with mild-moderate renal impairment. Metastatic bone pain may respond to strong opioids, bisphosphonates, or radiotherapy, and referral to a clinical oncologist should be considered. Conversion factors between opioids are provided, and the next dose should be increased by 30-50% when adjusting the dose. Opioid side-effects are usually transient, but constipation can persist. Denosumab may also be used to treat metastatic bone pain.

To manage a postpartum haemorrhage, an ABCDE approach should be taken, with initial steps including compressing the uterus and catheterising the patient. This is known as ‘mechanical management’ and is appropriate for a primary postpartum haemorrhage (PPH) where uterine atony is the most common cause. IV warmed crystalloid should also be given. Medical management options such as IV oxytocin or IM/IV carboprost should only be considered if mechanical methods fail. It is important to note that IV carboprost should not be administered as it can lead to serious side effects.

Understanding Postpartum Haemorrhage

Postpartum haemorrhage (PPH) is a condition where a woman experiences blood loss of more than 500 ml after giving birth vaginally. It can be classified as primary or secondary. Primary PPH occurs within 24 hours after delivery and is caused by the 4 Ts: tone, trauma, tissue, and thrombin. The most common cause is uterine atony. Risk factors for primary PPH include previous PPH, prolonged labour, pre-eclampsia, increased maternal age, emergency Caesarean section, and placenta praevia.

In managing PPH, it is important to involve senior staff immediately and follow the ABC approach. This includes two peripheral cannulae, lying the woman flat, blood tests, and commencing a warmed crystalloid infusion. Mechanical interventions such as rubbing up the fundus and catheterisation are also done. Medical interventions include IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options such as intrauterine balloon tamponade, B-Lynch suture, ligation of uterine arteries, and hysterectomy may be considered if medical options fail to control the bleeding.

Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis. It is important to understand the causes and risk factors of PPH to prevent and manage this life-threatening emergency effectively.

Referral for oral retinoin is recommended for patients with scarring.

Acne vulgaris is a common skin condition that typically affects adolescents, with the face, neck, and upper trunk being the most commonly affected areas. It is characterized by the obstruction of hair follicles with keratin plugs, leading to the formation of comedones, inflammation, and pustules. The severity of acne can be classified as mild, moderate, or severe, depending on the presence and extent of inflammatory lesions, papules, and pustules.

The management of acne vulgaris typically involves a step-up approach, starting with single topical therapy such as topical retinoids or benzoyl peroxide. If this is not effective, topical combination therapy may be used, which includes a topical antibiotic, benzoyl peroxide, and topical retinoid. Oral antibiotics such as tetracyclines may also be prescribed, but they should be avoided in pregnant or breastfeeding women and children under 12 years of age. Erythromycin may be used in pregnancy, while minocycline is now considered less appropriate due to the possibility of irreversible pigmentation. Oral antibiotics should be used for a maximum of three months and always co-prescribed with a topical retinoid or benzoyl peroxide to reduce the risk of antibiotic resistance.

Combined oral contraceptives (COCP) are an alternative to oral antibiotics in women, and Dianette (co-cyrindiol) may be used as it has anti-androgen properties. However, it has an increased risk of venous thromboembolism compared to other COCPs, so it should generally be used second-line and for only three months. Oral isotretinoin is a potent medication that should only be used under specialist supervision, and it is contraindicated in pregnancy. Finally, there is no evidence to support dietary modification in the management of acne vulgaris.

Given the patient’s syncope, low BP, and regular wide complex tachycardia, which is likely to be ventricular tachycardia, the appropriate next step is DC cardioversion since the systolic BP is below 90 mmHg. Adenosine is not relevant in this scenario as it is used for managing narrow complex regular tachycardia with no adverse features. Amiodarone is an antiarrhythmic medication that could be used to treat ventricular tachycardia, but it is not appropriate in this case due to the patient’s syncope and low BP.

Management of Peri-Arrest Tachycardias

The Resuscitation Council (UK) guidelines for the management of peri-arrest tachycardias have been simplified in the 2015 update. The previous separate algorithms for broad-complex tachycardia, narrow complex tachycardia, and atrial fibrillation have been replaced by a unified treatment algorithm. After basic ABC assessment, patients are classified as stable or unstable based on the presence of adverse signs such as hypotension, pallor, sweating, confusion, or impaired consciousness. If any of these signs are present, synchronised DC shocks should be given, up to a maximum of three shocks.

The treatment following this is based on whether the QRS complex is narrow or broad and whether the rhythm is regular or irregular. For broad-complex tachycardia, a loading dose of amiodarone followed by a 24-hour infusion is given if the rhythm is regular. If the rhythm is irregular, expert help should be sought as it could be due to atrial fibrillation with bundle branch block, atrial fibrillation with ventricular pre-excitation, or torsade de pointes.

For narrow-complex tachycardia, vagal manoeuvres followed by IV adenosine are given if the rhythm is regular. If unsuccessful, atrial flutter is considered, and rate control is achieved with beta-blockers. If the rhythm is irregular, it is likely due to atrial fibrillation, and electrical or chemical cardioversion is considered if the onset is less than 48 hours. Beta-blockers are usually the first-line treatment for rate control unless contraindicated. The full treatment algorithm can be found on the Resuscitation Council website.

The diagnosis can be inferred as a result of the short incubation period and intense vomiting.

Gastroenteritis can occur either at home or while traveling, known as travelers’ diarrhea. This condition is characterized by at least three loose to watery stools in 24 hours, accompanied by abdominal cramps, fever, nausea, vomiting, or blood in the stool. The most common cause of travelers’ diarrhea is Escherichia coli. Acute food poisoning is another pattern of illness that results in sudden onset of nausea, vomiting, and diarrhea after ingesting a toxin. Staphylococcus aureus, Bacillus cereus, or Clostridium perfringens are typically responsible for acute food poisoning.

There are several types of infections that can cause gastroenteritis, each with its own typical presentation. Escherichia coli is common among travelers and causes watery stools, abdominal cramps, and nausea. Giardiasis results in prolonged, non-bloody diarrhea, while cholera causes profuse, watery diarrhea and severe dehydration leading to weight loss. Shigella causes bloody diarrhea, vomiting, and abdominal pain, while Staphylococcus aureus results in severe vomiting with a short incubation period. Campylobacter typically starts with a flu-like prodrome and progresses to crampy abdominal pains, fever, and diarrhea, which may be bloody and mimic appendicitis. Bacillus cereus can cause two types of illness, vomiting within six hours, typically due to rice, or diarrheal illness occurring after six hours. Amoebiasis has a gradual onset of bloody diarrhea, abdominal pain, and tenderness that may last for several weeks.

The incubation period for gastroenteritis varies depending on the type of infection. Staphylococcus aureus and Bacillus cereus have an incubation period of 1-6 hours, while Salmonella and Escherichia coli have an incubation period of 12-48 hours. Shigella and Campylobacter have an incubation period of 48-72 hours, while Giardiasis and Amoebiasis have an incubation period of more than seven days.

When it comes to managing chronic pain, drugs for neuropathic pain are typically used alone. If they are not effective, it is recommended to switch to a different drug rather than adding another one. This question may also bring attention to poorly controlled acute pain, but it is important to note that morphine sulfate is not ideal for chronic pain management due to its potential side effects, dependence, and worsening of chronic pain. Tramadol is a better option for managing breakthrough pain in neuropathic pain patients, but it does not change the overall management of chronic pain. The recommended drugs for neuropathic pain include duloxetine, gabapentinoids, and amitriptyline (a tricyclic antidepressant).

Understanding Neuropathic Pain and its Management

Neuropathic pain is a type of pain that occurs due to damage or disruption of the nervous system. It is a complex condition that is often difficult to treat and does not respond well to standard painkillers. Examples of neuropathic pain include diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and prolapsed intervertebral disc.

To manage neuropathic pain, the National Institute for Health and Care Excellence (NICE) updated their guidance in 2013. The first-line treatment options include amitriptyline, duloxetine, gabapentin, or pregabalin. If the first-line drug treatment does not work, patients may try one of the other three drugs. Unlike standard painkillers, drugs for neuropathic pain are typically used as monotherapy, meaning that if they do not work, patients should switch to a different drug rather than adding another one.

Tramadol may be used as rescue therapy for exacerbations of neuropathic pain, while topical capsaicin may be used for localized neuropathic pain, such as post-herpetic neuralgia. Pain management clinics may also be useful for patients with resistant problems. However, it is important to note that for some specific conditions, such as trigeminal neuralgia, the guidance may vary, and carbamazepine may be used as a first-line treatment. Overall, understanding neuropathic pain and its management is crucial for improving the quality of life for patients suffering from this condition.

Osteopaenia and osteoporosis are associated with prolonged use of corticosteroids, not osteomalacia.

Understanding Corticosteroids and Their Side-Effects

Corticosteroids are commonly prescribed therapies used to replace or augment the natural activity of endogenous steroids. They can be administered systemically or locally, depending on the condition being treated. However, the usage of corticosteroids is limited due to their numerous side-effects, which are more common with prolonged and systemic therapy.

Glucocorticoid side-effects include impaired glucose regulation, increased appetite and weight gain, hirsutism, hyperlipidaemia, Cushing’s syndrome, moon face, buffalo hump, striae, osteoporosis, proximal myopathy, avascular necrosis of the femoral head, immunosuppression, increased susceptibility to severe infection, reactivation of tuberculosis, insomnia, mania, depression, psychosis, peptic ulceration, acute pancreatitis, glaucoma, cataracts, suppression of growth in children, intracranial hypertension, and neutrophilia.

On the other hand, mineralocorticoid side-effects include fluid retention and hypertension. It is important to note that patients on long-term steroids should have their doses doubled during intercurrent illness. Longer-term systemic corticosteroids suppress the natural production of endogenous steroids, so they should not be withdrawn abruptly as this may precipitate an Addisonian crisis. The British National Formulary suggests gradual withdrawal of systemic corticosteroids if patients have received more than 40mg prednisolone daily for more than one week, received more than three weeks of treatment, or recently received repeated courses.